A clinical trial involving more than 1,200 participants at 374 sites in 17 countries has found that a new drug called benralizumab has the potential to safely improve outcomes for people with severe asthma.
The study, called SIROCCO, is published in the Sept. 5 issue of The Lancet Respiratory Medicine.
“Our results showed that benralizumab significantly reduced exacerbations and improved lung function with an acceptable safety profile for patients with severe uncontrolled asthma with eosinophilia,” said the study’s lead author, Eugene R. Bleecker, M.D., director of the Center for Genomics and Personalized Medicine Research at Wake Forest Baptist Medical Center.
